Phaseline

Targets › HGNC

HGNC: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2027.

Open in Phaseline: the race on HGNC, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Inovio PharmaceuticalsINO-5401
DNA plasmid encoding WT1, PSMA, and hTERT tumor-associated antigens
WT1, PSMA, HGNCPhase 1GlioblastomaDec 2027

Conditions

Glioblastoma (1)

Modalities

mixed (1)

Companies

Inovio Pharmaceuticals (1)

Related targets

WT1 (1) PSMA (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.